The quality of three decision-analytic diabetes models: A systematic health economic assessment

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 6, 2011, Pages 751-762

  Becker, Christian ^a,b   Langer, Astrid ^a,b   Leidl, Reiner ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

cost analysis; costs; decision support techniques; economic model; Type 2 diabetes mellitus

Indexed keywords

ARCHIMEDES MODEL; ARTICLE; CDC MODEL; CENTER FOR OUTCOMES RESEARCH DIABETES MODEL; COMPUTER SIMULATION; DECISION SUPPORT SYSTEM; DIABETES MELLITUS; DISEASE MODEL; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH ECONOMICS; MARKOV MODEL; MEDICAL DECISION MAKING; MONTE CARLO METHOD; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL;

COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEASIBILITY STUDIES; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; MODELS, THEORETICAL; MONTE CARLO METHOD; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 81755171252     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.68     Document Type: Article

References (31)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004).
2. Zhang P, Zhang X, Brown J et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87(3), 293-301 (2010).
3. Stahl JE. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmacoeconomics 26(2), 131-148 (2008).
4. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ. 5(1), 1-11 (1996).
5. Higgins JPT, Green S; Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Wiley-Blackwell, Chichester, England; NJ, USA (2008).
6. Centre for Reviews and Dissemination. Systematic Reviews CRD's Guidance for Undertaking Reviews in Health Care. York Publishing Service Ltd, York, England (2009).
7. Evers S, Goossens M, De Vet H, Van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on Health Economic Criteria. Int. J. Technol. Assess. Health Care 21(2), 240-245 (2005).
8. Tarride J-E, Hopkins R, Blackhouse G et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics 28(4), 255-277 (2010).
9. Yi Y, Philips Z, Bergman G, Burslem K. Economic models in Type 2 diabetes. Curr. Med. Res. Opin. 26(9), 2105-2118 (2010).
10. The Mount Hood 4 Modelling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 30(6), 1638-1646 (2007).
11. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 24(4), 355-371 (2006).
12. Philips Z, Ginnelly L, Sculpher M et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol. Assess. 8(36), iii-iv, ix-xi, 1-158 (2004).
13. Soto J. Health economic evaluations using decision analytic modeling. Principles and practices - utilization of a checklist to their development and appraisal. Int. J. Technol. Assess. Health Care 18(1), 94-111 (2002).
14. Weinstein MC, Toy EL, Sandberg EA et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 4(5), 348-361 (2001).
15. American Diabetes Association. Guidelines for computer modelling of diabetes and its consequences. Diabetes Care 27(9), 2262-2265 (2004).
16. CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for Type 2 diabetes. JAMA 287(19), 2542-2551 (2002).
17. Palmer AJ, Roze SP, Lammert M et al. Comparing the long-term cost- effectiveness of repaglinide plus metformin versus nateglinide plus metformin in Type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in Type 2 diabetes. Curr. Med. Res. Opin. 20(Suppl. 1), S41-S51 (2004).
18. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann. Intern. Med. 143(4), 251-264 (2005).
19. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am. J. Public Health 77(11), 1417-1426 (1987).
20. Brändle M, Herman WH. The CORE Diabetes Model. Curr. Med. Res. Opin. 20 (Suppl. 1), S1-S3 (2004).
21. Palmer A, Roze S, Valentine W et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Curr. Med. Res. Opin. 20(Suppl. 1), S5-S26 (2004).
22. Palmer AJ, Roze S, Valentine WJ et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr. Med.Res. Opin. 20 (Suppl. 1), S27-S40 (2004).
23. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 26(11), 3093-3101 (2003).
24. Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems - the mathematical formulation. J. Biomed. Inform. 35(1), 37-50 (2002).
25. Eddy DM, Schlessinger L. Validation of the Archimedes Diabetes Model. Diabetes Care 26(11), 3102-3110 (2003).
26. Buxton MJ, Drummond MF, Van Hout BA et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 6(3), 217-227 (1997).
27. Eddy D. Bringing health economic modeling to the 21st century. Value Health 9(3), 168-178 (2006).
28. Schramm W, Schöll M, Trinczek B, Weber C. The prosit disease modelling community - open source development of decision analytic disease models for Type 2 diabetes. ISPOR 10th European Congress Research Abstracts. Value Health 10(6), A274 (2007).
29. Waugh N, Cummins E, Royle P et al. Newer agents for blood glucose control in Type 2 diabetes: systematic review and economic evaluation. Health Technol. Assess. 14(36), 1-248 (2010).
30. Ferdinands JM, Mannino DM. Obstructive lung disease models: what is valid? COPD 5(6), 382-393 (2008).
31. Stearns SC, Drummond M. Grading systems for cost-effectiveness studies: is the whole greater than the sum of the parts? Med. Care 41(1), 1-3 (2003).